World

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor
AJMC Contributor
0 Min Read
Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

This post was originally published on this site

Previous Article Growing conservative movement in Canada is fighting back against ‘California on steroids,’ says strategist
Next Article Elon Musk Is Trying to Break Germany’s Quarantine on the Far-Right AfD
Trump challenges kamala harris to three debates in september. : john’s tummy tuck scar is transformed into a unique aspect of his body art, boosting his confidence in his appearance. Spacex reveals game changing 1tbps bandwidth for v3 starlink satellites.